A pharmaceutical innovation: Is it worth the money? Whose money?

Arbeitspapier

This study seeks to provide evidence for deciding whether or not a pharmaceutical innovation should be included in the benefit list of social health insurance. A discrete choice experiment (DCE) was conducted in Germany to measure preferences for modern insulin therapy. Of the 1,100 individuals interviewed in 2007, 200 suffered from type 1 diabetes, 150 from insulin-treated type 2 diabetes, and 150 from insulin-naive type 2 diabetes. The long-acting insulin analogue 'Insulin Detemir' is compared to human insulin as the status quo. The DCE contains two price attributes, copayment and increased contributions to health insurance. As one would expect, non-affected non-diabetics and insulin-naive diabetics exhibit higher willingness-to-pay (WTP) values through copayment (adjusted for probability of contracting diabetes), while affected type 1 and insulin-treated type 2 diabetics have higher WTP through increased contributions. However, WTP values exceed the extra treatment cost in both financing alternatives, justifying inclusion of the innovation in the benefit list from a cost-benefit point of view.

Angaben zum Objekt

• Sprache: Englisch

Verweise und Beziehungen

• Erschienen in: Series: Working Paper ; No. 0914

Klassifikation und Themen

• Klassifikation: Wirtschaft ; Analysis of Health Care Markets ; National Government Expenditures and Health ; Health: Government Policy; Regulation; Public Health
• Thema: health insurance ; discrete-choice experiment ; preferences ; diabetes ; Innovation ; Pharmazeutisches Produkt ; Diskrete Entscheidung ; Gesundheitsversorgung ; Test ; Deutschland

Beteiligte, Orts- und Zeitangaben

• Ereignis: Geistige Schöpfung
• (wer): Sennhauser, Michèle ; Zweifel, Peter
• Ereignis: Veröffentlichung
• (wer): University of Zurich, Socioeconomic Institute
• (wo): Zurich
• (wann): 2009

Weitere Informationen

• Handle: http://hdl.handle.net/10419/76135
• Letzte Aktualisierung: 10.03.2025, 11:42 MEZ